比较左西孟旦与米力农对急性心肌梗死合并心力衰竭患者B型利钠肽及主要心血管不良事件的影响

Comparison of the Effects of Levosimendan and Milrinone on B-Type Natriuretic Peptide and Major Cardiovascular Adverse Events in Patients with Acute Myocardial Infarction and Heart Failure

目的比较左西孟旦与米力农对急性心肌梗死(AMI)合并心力衰竭(HF)患者B型利钠肽及主要心血管不良事件的影响。方法选取2020年5月—2023年5月金乡县人民医院收治的84例AMI合并HF患者为研究对象,按照随机数字表法将其分为对照组和观察组,各42例。对照组采用米力农治疗,观察组采用左西孟旦治疗。对比两组的临床疗效、心功能指标、血清B型尿钠肽(BNP)水平及主要心血管不良事件发生率。结果观察组治疗总有效率为61.90%,高于对照组的33.33%,差异有统计学意义(P<0.05)。治疗后,观察组左心室射血分数高于对照组,左心室收缩末期内径及左室舒张末期内径均短于对照组,血清BNP水平低于对照组,组间差异有统计学意义(P<0.05)。观察组主要心血管不良事件发生率为7.14%,低于对照组的23.81%,差异有统计学意义(P<0.05)。结论相较于米力农,采用左西孟旦治疗AMI合并HF患者的效果更佳,可有效改善患者的心功能,降低血清BNP水平及主要心血管不良事件发生率,较为安全。

Objective To compare the effects of levosimendan and milrinone on B-type natriuretic peptide and major cardiovascular adverse events in patients with acute myocardial infarction(AMI)and heart failure(HF).Methods A total of 84 patients with AMI combined with HF admitted to the Jinxiang Conurty People's Hospital from May 2020 to May 2023 were selected as the research subjects.They were randomly divided into a control group and an observation group using a random number table method,with 42 cases in each group.The control group was treated with milrinone,while the observation group was treated with levosimendan.Compare the clinical efficacy,cardiac function indicators,serum B-type natriuretic peptide(BNP)levels,and major cardiovascular adverse events between two groups.Results The total effective rate of the observation group was 61.90%,higher than 33.33%of the control group,and the difference was statistically significant(P<0.05).After treatment,the left ventricular ejection fraction in the observation group was higher than that in the control group,the left ventricular end systolic diameter and left ventricular end diastolic diameter were both shorter than those in the control group,the serum BNP level was lower than that in the control group,and the differences between the groups were statistically significant(P<0.05).The incidence of major cardiovascular adverse events in the observation group was 7.14%,lower than 23.81%in the control group,and the difference was statistically significant(P<0.05).Conclusion Compared to milrinone,the use of levosimendan in the treatment of AMI patients with HF is more effective,can effectively improve heart function,reduce serum BNP levels and the incidence of major cardiovascular adverse events,and is safer.